Expression of tNASP in Prostate Cancer: Opportunities for a Novel Diagnostic and Prognostic Biomarker Development
Final rept. 30 Sep 2012-29 Sep 2013
NORTH CAROLINA UNIV AT CHAPEL HILL
Pagination or Media Count:
This project offers an exploration of a new line of diagnostics for prostate cancer. It is based on the expression of tNASP protein in prostate cancer cells. We propose to detect anti-tNASP antibodies in the serum of prostate cancer patients for screening purposes and to distinguish prostate cancer from BPH. Detection of tNASP protein expression levels in needle biopsies and postoperative prostate cancer samples will be correlated with pathologic indicators of aggressive prostate cancer for diagnostic and prognostic purposes. We propose two specific aims Specific aim 1 will validate the detection of anti-tNASP antibodies as serum-based biomarkers of prostate cancer. This aim will address the hypothesis that tNASP-specific antibodies are present in the blood of prostate cancer patients, but not BPH patients or otherwise healthy men. We will test the hypothesis that presence of tNASP-specific antibodies is an early marker of prostate cancer and that, together with PSA assay, it could be used as a screening method for early detection in high-risk population groups. Specific aim 2 will validate the utility of tNASP protein as a tissue-based diagnostic and prognostic biomarker of prostate cancer. We will address the hypothesis that expression of tNASP in prostate tissue samples obtained during needle biopsies can be used to diagnose prostate cancer and to differentiate between BPH and malignant tumor. The second part of this aim will test the hypothesis that advanced and aggressive prostate cancers show higher expression of tNASP protein than early stage tumors.
- Medicine and Medical Research